DarioHealth (NASDAQ: DRIO) prices $23.5M registered direct stock and warrant deal
Rhea-AI Filing Summary
DarioHealth Corp. is conducting a registered direct offering of 3,454,559 shares of common stock (or common stock equivalents) at $6.80 per share, for aggregate gross proceeds of approximately $23.5 million before fees and expenses. The securities include 2,437,060 shares of common stock and pre-funded warrants to purchase 1,017,499 shares at $6.7999 per warrant.
Board member Dennis Matheis is purchasing 14,430 additional shares at $6.93 per share. The pre-funded warrants are immediately exercisable but have beneficial ownership limits that generally restrict any holder and its affiliates from exceeding 4.99% or 9.99% ownership without advance notice or, in some cases, shareholder approval.
A.G.P./Alliance Global Partners is acting as sole placement agent, earning a 6.0% cash fee on most gross proceeds (1.0% for certain investors) plus up to $60,000 of reimbursed expenses. For 30 days after closing, the company agreed not to issue most new equity or file additional registration statements, while retaining the ability to use its existing at-the-market facility. Net proceeds are intended for working capital, investments, acquisitions, and general corporate purposes.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total shares or equivalents offered: 3,454,559 shares
Common shares in offering: 2,437,060 shares
Pre-funded warrant shares: 1,017,499 shares
+5 more
8 metrics
Total shares or equivalents offered
3,454,559 shares
Common stock (or common stock equivalents) sold at $6.80 per share in the offering
Common shares in offering
2,437,060 shares
Shares of common stock sold to institutional investors
Pre-funded warrant shares
1,017,499 shares
Shares of common stock underlying pre-funded warrants
Offering price per share
$6.80 per share
Price for common stock and common stock equivalents in registered direct offering
Pre-funded warrant price
$6.7999 per warrant
Offering price for each pre-funded warrant
Gross proceeds
approximately $23.5 million
Aggregate gross proceeds before placement agent fees and expenses
Director share purchase
14,430 shares at $6.93 per share
Purchased by board member Dennis Matheis in the offering
Placement agent fees
6.0% and 1.0% of gross proceeds
6.0% fee generally; 1.0% fee for certain investors’ proceeds
Key Terms
registered direct offering, pre-funded warrants, At-The-Market facility, beneficially own, +2 more
6 terms
registered direct offering financial
"agreed to issue and sell to the investors in a registered direct offering priced at-the-market"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
pre-funded warrants financial
"and pre-funded warrants to purchase an aggregate of 1,017,499 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
At-The-Market facility financial
"during the Restricted Period, the Company is permitted to make sales under its existing At-The-Market facility"
An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.
beneficially own regulatory
"may not exercise the warrant if the holder... would beneficially own more than 4.99% (or... 9.99%)"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shelf registration statement regulatory
"offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-294454)"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
placement agent financial
"engaged the Placement Agent as the exclusive placement agent in connection with the Offering"
A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.
Offering Details
shelf
Offering
Offering Type
shelf
Use of Proceeds
Working capital, investments, acquisitions, and general corporate purposes
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is DarioHealth (DRIO) raising in its July 2026 registered direct offering?
DarioHealth is raising approximately $23.5 million through a registered direct offering of 3,454,559 shares of common stock (or equivalents) at $6.80 per share. This includes common shares and pre-funded warrants sold to institutional investors.
How is the DarioHealth (DRIO) July 2026 offering structured?
The offering consists of 2,437,060 common shares and pre-funded warrants to purchase 1,017,499 shares, each warrant priced at $6.7999. A director is separately buying 14,430 shares at $6.93 per share in the same financing.
What are the terms of the pre-funded warrants in DarioHealth’s (DRIO) deal?
The pre-funded warrants are exercisable at any time after issuance with ownership limits of 4.99% or 9.99%. Holders generally cannot exceed these beneficial ownership levels without 61 days’ notice or, in some cases, shareholder approval for higher ownership.
How will DarioHealth (DRIO) use the proceeds from this offering?
DarioHealth plans to use the net proceeds for working capital, investments, acquisitions, and general corporate purposes. These funds are intended to support ongoing operations and potential strategic initiatives across its AI-powered chronic condition management platform.
What fees is DarioHealth (DRIO) paying to the placement agent in this transaction?
A.G.P./Alliance Global Partners will receive a 6.0% cash fee on most gross proceeds and 1.0% on certain investors’ funds. DarioHealth will also reimburse up to $60,000 of the placement agent’s legal and other expenses at closing.
Are there issuance restrictions after DarioHealth’s (DRIO) July 2026 offering?
For 30 days after closing, DarioHealth agreed not to issue most new common stock or equivalents or file additional registration statements. It may still use its existing At-The-Market facility and file Form S-8 for employee benefit plans.